Capital Southwest Announces Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2025

2 days ago

DALLAS, May 14, 2025 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest,” “CSWC” or the “Company”) (Nasdaq: CSWC), an internally…

Conifer Holdings Reports 2025 First Quarter Financial Results

2 days ago

TROY, Mich., May 14, 2025 (GLOBE NEWSWIRE) -- Conifer Holdings, Inc. (Nasdaq: CNFR) (“Conifer” or the “Company”) today announced results…

Monogram Technologies Reports First Quarter 2025 Financial Results

2 days ago

Receives FDA Clearance for the mBôs™ TKA System Groundbreaking Trial Set to Deliver one of the World’s First Autonomous Saw-Based…

Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress

2 days ago

Conference call today, May 14, 2025, at 4:30 PM ETSAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc.…

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

2 days ago

On track to report topline results from Phase 2 BESTOW trial in kidney transplantation in fourth quarter of 2025 Tegoprubart…

Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

2 days ago

The primary completion date of the PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is expected in June 2025…

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

2 days ago

Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus…

Usio Announces First Quarter 2025 Financial Results

2 days ago

Record First Quarter Revenues of $22.0 million Total payment dollars processed through all payment channels up 34% versus the prior year period …

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

2 days ago

Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial…

scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

2 days ago

Generated net FUROSCIX® revenue of $11.8 million in the first quarter of 2025 Formally launched FUROSCIX in second approved indication,…

This website uses cookies.